NCT01664065View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetics of Ceftaroline in End Stage Renal Disease Patients and Matched Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Renal Disease
Interventions
DRUG

200 mg Ceftaroline fosamil

1 h infusion

DRUG

600 mg Ceftaroline fosamil

1 h infusion

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01664065 - A Study to Assess the Pharmacokinetics of Ceftaroline in End Stage Renal Disease Patients and Matched Healthy Subjects | Biotech Hunter | Biotech Hunter